Nevro (NVRO) Stock Forecast & Price Target

$5.82

-0.03 (-0.51%)

(As of 09/18/2024 ET)

Nevro - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Reduce
Based on 14 Analyst Ratings

Based on 14 Wall Street analysts who have issued ratings for Nevro in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 14 analysts, 3 have given a sell rating, and 11 have given a hold rating for NVRO.

Consensus Price Target

$10.63
82.58% Upside

High Forecast	$23.00
Average Forecast	$10.63
Low Forecast	$5.50

According to the 14 analysts' twelve-month price targets for Nevro, the average price target is $10.63. The highest price target for NVRO is $23.00, while the lowest price target for NVRO is $5.50. The average price target represents a forecasted upside of 82.58% from the current price of $5.82.

Type	Current Forecast 9/20/23 to 9/19/24	1 Month Ago 8/21/23 to 8/20/24	3 Months Ago 6/22/23 to 6/21/24	1 Year Ago 9/20/22 to 9/20/23
Consensus Rating	Reduce	Reduce	Reduce	Hold
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	0 Buy rating(s)	0 Buy rating(s)	1 Buy rating(s)	4 Buy rating(s)
Hold	11 Hold rating(s)	11 Hold rating(s)	10 Hold rating(s)	8 Hold rating(s)
Sell	3 Sell rating(s)	3 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$10.63	$10.63	$19.46	$30.62
Forecasted Upside	82.58% Upside	11.85% Upside	26.91% Upside	27.75% Upside

Wall St. Icon: Looming Financial Tsunami will Wipe Out the 1% (Ad)

Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event will hit the American economy like a tsunami. It doesn't matter if you're blue collar, white collar, working, or retired. He says, "I am literally afraid for my family's future. I'm taking drastic steps to prepare for what I know will inevitably happen next."

Click here to see his new prediction

NVRO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

NVRO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Nevro Stock vs. The Competition

Type	Nevro	Medical Companies	S&P 500
Consensus Rating Score	1.79	2.77	2.50
Consensus Rating	Reduce	Moderate Buy	Moderate Buy
Predicted Upside	82.58% Upside	1,009.46% Upside	7.94% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/9/2024	Citigroup 3 of 5 stars	J. Wuensch Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell ➝ Neutral	$6.89	+21.52%
8/8/2024	Truist Financial 1 of 5 stars		Lower Target	Hold ➝ Hold	$10.00 ➝ $5.50	+13.17%
8/8/2024	Wolfe Research 3 of 5 stars	M. Polark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Peer Perform
8/7/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Sector Perform ➝ Sector Perform	$16.00 ➝ $7.00	+41.99%
8/7/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$11.00 ➝ $8.00	+51.52%
8/7/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Underweight ➝ Underweight	$12.00 ➝ $7.00	-19.45%
Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (Ad) Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now. Click here to see it because it’s a SHOCKER…
8/7/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Turkaly Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
8/7/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Underweight
8/7/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	N. Treybeck Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Equal Weight ➝ Underweight	$13.00 ➝ $5.50	-36.71%
7/15/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$14.00 ➝ $9.00	-4.26%
5/8/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$17.00 ➝ $11.00	+5.97%
4/11/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$20.00 ➝ $16.00	+20.30%
2/22/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
11/2/2022	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Vazquez Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
10/12/2022	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Underperform	$31.00	-16.98%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 05:35 AM ET.

NVRO Forecast - Frequently Asked Questions

What is Nevro's forecast for 2024?: According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Nevro is $10.63, with a high forecast of $23.00 and a low forecast of $5.50.
Should I buy or sell Nevro stock right now?: 14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 3 sell ratings and 11 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "reduce" NVRO shares.
Does Nevro's stock price have much upside?: According to analysts, Nevro's stock has a predicted upside of 11.85% based on their 12-month stock forecasts.
Has Nevro been upgraded or downgraded by Wall Street analysts recently?: Over the previous 90 days, Nevro's stock had 3 downgrades and 2 upgrades by analysts.
What analysts cover Nevro?: Nevro has been rated by research analysts at Citigroup, JMP Securities, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, Robert W. Baird, Royal Bank of Canada, Truist Financial, Wells Fargo & Company, and Wolfe Research in the past 90 days.
Do Wall Street analysts like Nevro more than its competitors?: Analysts like Nevro less than other "medical" companies. The consensus rating for Nevro is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how NVRO compares to other companies.